<DOC>
	<DOCNO>NCT00979940</DOCNO>
	<brief_summary>This research study plan evaluate use atorvastatin patient coronary artery disease give immediately PCI whether decrease amount heart damage PCI .</brief_summary>
	<brief_title>Effects Short Term , High Dose Atorvastatin Therapy Periprocedural Myonecrosis Platelet Inhibition After Percutaneous Coronary Intervention ( PCI )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>patient undergoing revascularization significant coronary artery disease age range 2185 year nonSTEMI , STEMI cancer renal failure creatinine &gt; 3.0mg/dl liver cirrhosis lymphoproliferative disorder pregnancy thrombocytopenia &lt; 150'000 coagulopathy ( INR &gt; 1.5 ) abnormal liver function test illicit drug use history statin intolerance history rhabdomyolysis plan use Glycoprotein IIb/IIIa inhibitor PCI current therapy atorvastatin , pravastatin , lovastatin , fluvastatin , rosuvastatin</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>atorvastatin</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>percutaneous intervention</keyword>
	<keyword>periprocedural myonecrosis</keyword>
</DOC>